Nestlé: Aimmune's allergy drug gets positive CHMP opinion

(CercleFinance.com) - Aimmune Therapeutics, now a Nestlé unit, said it received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending its peanut allergy treatment.


The committee adopted a positive opinion on Palforzia for the treatment of peanut allergy in patients aged 4-17 years in the European Union, Aimmune said.

The EMA is an agency of the European Union responsible for the evaluation of medicines submitted for approval by pharmaceutical companies for use in the 28 countries of the European Union.

The European Commission's final decision is anticipated in the fourth quarter of 2020, Aimmune said.

Copyright (c) 2020 CercleFinance.com. All rights reserved.